Clinical Trials Logo

Postmenopausal Osteoporosis clinical trials

View clinical trials related to Postmenopausal Osteoporosis.

Filter by:
  • Recruiting  
  • Page 1 ·  Next »

NCT ID: NCT06079476 Recruiting - Clinical trials for Postmenopausal Osteoporosis

A Study of Romosozumab (EVENITY®) in Postmenopausal Women in India With Osteoporosis at a High Risk of Fracture.

Start date: October 30, 2023
Phase: Phase 4
Study type: Interventional

The primary objective of this study is to characterize safety and tolerability of romosozumab in postmenopausal women with osteoporosis and a high risk of fracture in India.

NCT ID: NCT05630768 Recruiting - Clinical trials for Postmenopausal Osteoporosis

Efficacy and Safety of Actonel® After Denosumab Discontinuation in Postmenopausal Osteoporosis Women

Start date: January 3, 2023
Phase: Phase 4
Study type: Interventional

To evaluate the effect of 1 year of risedronate treatment on the prevention of bone loss after denosumab discontinuation in denosumab-treated post-menopausal osteoporosis for a year

NCT ID: NCT05405725 Recruiting - Clinical trials for Postmenopausal Osteoporosis

A Phase 3 Study to Compare Biosimilar Denosumab With Prolia®

Start date: July 4, 2022
Phase: Phase 3
Study type: Interventional

This is a phase 3 Randomized, Double-blind, Parallel-group, Active-controlled Study to Compare the Efficacy, Safety, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Enzene Denosumab (ENZ215) and Prolia® in Postmenopausal Women with Osteoporosis

NCT ID: NCT05278338 Recruiting - Clinical trials for Postmenopausal Osteoporosis

Efficacy and Safety of JMT103 in the Treatment of Postmenopausal Women With Osteoporosis

Start date: April 21, 2022
Phase: Phase 2
Study type: Interventional

This study is to evaluate the efficacy and safety of JMT103 in the treatment of postmenopausal women with osteoporosis.

NCT ID: NCT05060406 Recruiting - Clinical trials for Postmenopausal Osteoporosis

A Study to Evaluate the Efficacy and Safety of LY06006 in Postmenopausal Women With Osteoporosis at High Risk for Fracture

Start date: June 30, 2019
Phase: Phase 3
Study type: Interventional

A multicenter, randomized, double-blind, placebo-controlled phase III clinical study will be conducted to evaluate the efficacy and safety of LY06006 in the treatment of postmenopausal women with osteoporosis at high risk for fracture, as well as an exploratory population pharmacokinetic analysis of LY06006.

NCT ID: NCT04940845 Recruiting - Clinical trials for Postmenopausal Osteoporosis

Comparing of the Pharmacokinetic, Safety and Immunogenicity of HS-20090-2 Injection and Prolia® in Healthy Adults

Start date: July 26, 2021
Phase: Phase 1
Study type: Interventional

A randomized, single-blind and parallel group study to compare the pharmacokinetic, safety and immunogenicity of HS-20090-2 60mg#1ml#and Prolia® in healthy adults.

NCT ID: NCT04591275 Recruiting - Clinical trials for Postmenopausal Osteoporosis

Clinical Efficacy and Safety Comparative Study Between CMAB807 Injection and Prolia® .

Start date: March 31, 2021
Phase: Phase 3
Study type: Interventional

evaluate the differences in effectiveness and safety between CMAB807( potential biosimilar) and Prolia(original product)

NCT ID: NCT04128163 Recruiting - Clinical trials for Postmenopausal Osteoporosis

Efficacy and Safety of QL1206 in the Treatment of Postmenopausal Osteoporosis With High Fracture Risk

Start date: June 5, 2019
Phase: Phase 3
Study type: Interventional

A randomized, double-blind, two-group parallel, placebo-controlled clinical Phase III trial to compare the efficacy and safety of QL1206 and placebo in postmenopausal women with osteoporosis at high risk of fracture

NCT ID: NCT02981732 Recruiting - Clinical trials for Postmenopausal Osteoporosis

CLCF1 Gene Associated With Postmenopausal Osteoporosis of Kidney Yin Deficiency Syndrome

PMOP
Start date: October 2016
Phase: N/A
Study type: Interventional

For nearly 112 million patients with osteoporosis in China, it is of great significance for preventing and treating by clearly understanding the molecular mechanism of kidney deficiency. Thus, the research group has demonstrated in the earlier research that CLCF1 is an associated gene that can regulate JAK2/STAT3 signal pathway and impact bone metabolism for kidney yin deficiency of postmenopausal osteoporosis (PMOP). To make clear understanding of the direct-acting mechanism of CLCF1 for bone metabolism, this study intends to: ①observe impacts of low expression of CLCF1 upon immunities in mice and OPG/RANKL/RANK signal system using the technology of adenovirus associated virus. ②explore impacts of over-expression and silencing of CLCF1 on B lymphocytes by culcuturing the cells together with osteoblasts. ③ analyze the impacts of treating kidney yin deficiency of PMOP by Liuwei Dihuang pill upon immunities and OPG/RANKL/RANK system, and discuss the mechanism of regulating bone metabolism by CLCF1 by OPG/RANKL/RANK system via the bridge between immune system and bone metabolism, so as to demonstrate if the hypothesis of this study that "the molecular osteoimmunological mechanism of kidney yin deficiency of postmenopausal osteoporosis (PMOP) is possibly closely related to the impacts of CLCF1 regulation of OPG/RANKL/RANK signal system on bone metabolism" is right or not.

NCT ID: NCT02854722 Recruiting - Clinical trials for Postmenopausal Osteoporosis

The Deferasirox-calcium-vitamin D3 Therapy for Postmenopausal Osteoporosis (PMOP)

PMOP
Start date: January 15, 2018
Phase: Phase 2
Study type: Interventional

In 2006, Weinberg proposed a hypothesis that iron accumulation was a risk factor for osteoporosis. Osteoporosis is a common complication in various diseases, such as hemochromatosis, African hemosiderosis, thalassemia, and sickle cell disease, which all share iron accumulation as a common denominator. Moreover, a 3-year retrospective longitudinal study has shown that iron accumulation was also associated with osteoporosis in healthy adults and especially that it can increase the risk of fractures in postmenopausal women. Based on these observations, iron chelation therapy may have a promising future in the treatment of iron accumulation-related osteoporosis by removing iron from the body. The purpose of this study is to determine whether the addition of the iron chelator, deferasirox, to standard therapy for postmenopausal osteoporosis, is safe and effective.